Bone Health
Receiving 3 to 5 years of bisphosphonate treatment after surgery and chemotherapy for early-stage breast cancer doesn’t improve survival any more than receiving 2 years of bisphosphonate treatment.
The combination of Zometa and Femara after surgery offered better disease-free survival than tamoxifen for premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer, but caused more side effects.
After a year of standard treatment, women with bone metastases can get Zometa every 12 weeks instead of 4 and get the same benefits from the medicine.
A study has found that Prolia improved disease-free survival for postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer taking an aromatase inhibitor.
A study found that Prolia reduced the risk of breaking a bone by 50% in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer who were taking an aromatase inhibitor.
All bisphosphonates seem to offer the same recurrence risk reduction benefits.
Two randomized studies found that 3 to 4 years of treatment with either Fosamax or zoledronic acid doesn't seem to reduce breast cancer risk in postmenopausal women.
A study suggests that after a year, women with bone metastases can get Zometa every 12 weeks instead of every 4 weeks and still get the same benefits from the medicine, while reducing their risk of side effects.
A large study has found that bisphosphonates reduce the risk of distant breast cancer recurrence in postmenopausal women.
Research suggests that people diagnosed with advanced-stage breast or prostate cancer who get Xgeva are about twice as likely to develop osteonecrosis of the jaw compared to people with other advanced-stage cancers treated with Xgeva.
The osteoporosis drug denosumab (Prolia) is now FDA-approved to treat bone loss in women taking aromatase inhibitors.
On Sept. 1, 2011 the U.S. Food and Drug Administration warned doctors and patients that Reclast may cause severe kidney problems.
Research has found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, is somewhat better than Zometa at lowering the risk of bone complications in women diagnosed with breast cancer that has spread to the bones.
Research suggests that Zometa, a medicine used to strengthen bones, may slow breast cancer growth.
A new selective estrogen receptor modulator (SERM) called Oporia (chemical name: lasofoxifene) has been shown to improve bone health and reduce the risk of breast cancer, especially hormone-receptor-positive breast cancer, in post-menopausal women.